Introduction
Fatty liver disease (also called non-alcoholic fatty liver disease, NAFLD) happens when fat builds up in the liver. In some people, it can progress to non-alcoholic steatohepatitis (NASH), scarring (fibrosis), or even cirrhosis.
Weight loss is the most effective way to improve fatty liver disease. Medicines such as Wegovy (semaglutide) and Mounjaro (tirzepatide) help with weight loss and may also directly benefit the liver.
GLP-1 Medicines and the Liver: What the Evidence Says
Weight loss effect: GLP-1 medicines support significant weight loss, which reduces fat in the liver and improves liver enzymes (1,2).
Direct effects on the liver: Studies suggest GLP-1s reduce liver inflammation and fat storage independently of weight loss (3).
Clinical trials:
Semaglutide improved liver fat and inflammation in people with NASH, although reversing advanced scarring remains challenging (4).
Tirzepatide is being studied and has shown promising reductions in liver fat on scans (5).
Overall: GLP-1 medicines are not yet licensed specifically for fatty liver disease, but they are showing strong benefits in research studies.
What Patients Should Consider:
1.Before starting treatment
Inform your GP of your intention to start using weight loss injections. You may need baseline blood tests to check liver function before starting which would be arranged by your GP.
Mounjaro is contraindicated in severe liver disease. Your GP should advise whether weight loss injections are safe for you to use, as well as your weight loss provider.
2. During treatment / Maintenance
Remember: fatty liver disease can sometimes progress to liver damage, so your GP will want to keep a close eye on your liver function.
You should attend regular liver function monitoring with your GP. This is important because side effects like fatigue, nausea, or abdominal pain may overlap with symptoms of liver disease. It is advisable to avoid excess alcohol, which can make liver problems worse.
3. After Stopping Treatment
Many patients see improved liver function and reduced fat in the liver after sustained weight loss.
Keep up lifestyle changes — fatty liver disease can return if weight is regained.
Your GP may reduce the frequency of blood tests if your liver improves, but long-term follow-up is still important.
4. When to Seek Medical Advice Urgently
Seek medical advice if you notice:
- Yellowing of the skin or eyes (jaundice)
- Swelling in the abdomen or legs
- Persistent or severe abdominal pain
- Dark urine or pale stools
- Severe tiredness or weakness
If these symptoms are sudden or severe, call 999 or attend A&E.
Lifestyle Tips to Support Liver Health
- Healthy weight loss: Even 5–10% weight loss can improve a fatty liver.
- Balanced diet: Focus on vegetables, wholegrains, lean protein, and reduce sugary foods and drinks.
- Regular exercise: Aim for 150 minutes of moderate activity each week.
- Limit alcohol: Ideally avoid alcohol if you have fatty liver disease.
Summary
GLP-1 medicines such as Wegovy and Mounjaro can help people with fatty liver disease by supporting weight loss and possibly reducing liver fat and inflammation.
They are not yet licensed specifically for fatty liver, but evidence is promising. With GP monitoring, regular liver function tests, and healthy lifestyle changes, these treatments can be used safely and may help protect your liver health.
References
- Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–90.
- Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113–24.
- Gupta NA, Mells J, Dunham RM, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis. World J Gastroenterol. 2010;16(42):5600–7.
- Newsome PN, Harrison SA, et al. Semaglutide 2.4 mg once weekly in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113–24.
- Gastaldelli A, Cusi K, et al. Tirzepatide reduces liver fat in adults with type 2 diabetes: MRI-PDFF results from SURPASS-3 trial. Diabetes Care. 2022;45(5):1011–9.